Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2000 2
2003 1
2005 1
2007 2
2008 1
2009 1
2012 1
2013 1
2016 2
2017 2
2018 1
2020 4
2021 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators. Pulido T, et al. N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917. N Engl J Med. 2013. PMID: 23984728 Free article. Clinical Trial.
BACKGROUND: Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end poi …
BACKGROUND: Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise c …
Tadalafil therapy for pulmonary arterial hypertension.
Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Galiè N, et al. Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Circulation. 2009. PMID: 19470885 Clinical Trial.
Changes in World Health Organization functional class, clinical worsening, and health-related quality of life were also assessed. Patients completing the 16-week study could enter a long-term extension study. Tadalafil increased the distance walked in 6 minutes in a dose-d …
Changes in World Health Organization functional class, clinical worsening, and health-related quality of life were also assessed. Patients c …
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.
Hoeper MM, Pausch C, Grünig E, Klose H, Staehler G, Huscher D, Pittrow D, Olsson KM, Vizza CD, Gall H, Benjamin N, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Rosenkranz S, Ewert R, Kaemmerer H, Lange TJ, Kabitz HJ, Skowasch D, Skride A, Jureviciene E, Paleviciute E, Miliauskas S, Claussen M, Behr J, Milger K, Halank M, Wilkens H, Wirtz H, Pfeuffer-Jovic E, Harbaum L, Scholtz W, Dumitrescu D, Bruch L, Coghlan G, Neurohr C, Tsangaris I, Gorenflo M, Scelsi L, Vonk-Noordegraaf A, Ulrich S, Held M. Hoeper MM, et al. Among authors: bruch l. J Heart Lung Transplant. 2020 Dec;39(12):1435-1444. doi: 10.1016/j.healun.2020.09.011. Epub 2020 Sep 30. J Heart Lung Transplant. 2020. PMID: 33082079 Free article.
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. ...
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension o …
Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.
Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Weilenmann D, Wöhrle J, Stachel G, Markovic S, Leibundgut G, Rickenbacher P, Osswald S, Cattaneo M, Gilgen N, Kaiser C, Scheller B; BASKET-SMALL 2 Investigators. Jeger RV, et al. Lancet. 2020 Nov 7;396(10261):1504-1510. doi: 10.1016/S0140-6736(20)32173-5. Epub 2020 Oct 19. Lancet. 2020. PMID: 33091360 Clinical Trial.
BACKGROUND: In the treatment of de-novo coronary small vessel disease, drug-coated balloons (DCBs) are non-inferior to drug-eluting stents (DESs) regarding clinical outcome up to 12 months, but data beyond 1 year is sparse. We aimed to test the long-term efficacy and safet …
BACKGROUND: In the treatment of de-novo coronary small vessel disease, drug-coated balloons (DCBs) are non-inferior to drug-eluting stents ( …
Infantile cranial fasciitis: case-based review and operative technique.
Flouty OE, Piscopo AJ, Holland MT, Abode-Iyamah K, Bruch L, Menezes AH, Dlouhy BJ. Flouty OE, et al. Among authors: bruch l. Childs Nerv Syst. 2017 Jun;33(6):899-908. doi: 10.1007/s00381-017-3417-y. Epub 2017 Apr 27. Childs Nerv Syst. 2017. PMID: 28451777 Review.
For these reasons, questions pertaining to the true incidence, genetic risk factors, prognosis, and long-term outcome remain unanswered. DISCUSSION: Clinically, CF presents as a firm, painless, growing scalp mass that is typically not considered in the differential diagnos …
For these reasons, questions pertaining to the true incidence, genetic risk factors, prognosis, and long-term outcome remain unanswer …
Single Center Experience with Isolated Spinal Cord Neurosarcoidosis.
Park BJ, Ray E, Bathla G, Bruch LA, Streit JA, Cho TA, Hitchon PW. Park BJ, et al. Among authors: bruch la. World Neurosurg. 2021 Dec;156:e398-e407. doi: 10.1016/j.wneu.2021.09.089. Epub 2021 Sep 25. World Neurosurg. 2021. PMID: 34583004
INTRODUCTION: Isolated spinal cord neurosarcoidosis is extremely rare. The potential implications of long-term immunosuppressant therapy make correct diagnosis imperative. ...
INTRODUCTION: Isolated spinal cord neurosarcoidosis is extremely rare. The potential implications of long-term immunosuppressant ther …
Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism: Analysis From a Prospective Multicenter Cohort Study.
Valerio L, Barco S, Jankowski M, Rosenkranz S, Lankeit M, Held M, Gerhardt F, Bruch L, Ewert R, Faehling M, Freise J, Ghofrani HA, Grünig E, Halank M, Hoeper MM, Klok FA, Leuchte HH, Mayer E, Meyer FJ, Neurohr C, Opitz C, Schmidt KH, Seyfarth HJ, Trudzinski F, Wachter R, Wilkens H, Wild PS, Konstantinides SV. Valerio L, et al. Among authors: bruch l. Chest. 2021 Jun;159(6):2428-2438. doi: 10.1016/j.chest.2021.01.071. Epub 2021 Feb 3. Chest. 2021. PMID: 33548221 Free article.
BACKGROUND: Few data are available on the long-term course and predictors of quality of life (QoL) following acute pulmonary embolism (PE). ...
BACKGROUND: Few data are available on the long-term course and predictors of quality of life (QoL) following acute pulmonary embolism …
Long-term outcome after thrombus aspiration in non-ST-elevation myocardial infarction: results from the TATORT-NSTEMI trial : Thrombus aspiration in acute myocardial infarction.
Feistritzer HJ, Meyer-Saraei R, Lober C, Böhm M, Scheller B, Lauer B, Geisler T, Gawaz M, Bruch L, Klein N, Zeymer U, Eitel I, Jobs A, Freund A, Desch S, de Waha-Thiele S, Thiele H. Feistritzer HJ, et al. Among authors: bruch l. Clin Res Cardiol. 2020 Oct;109(10):1223-1231. doi: 10.1007/s00392-020-01613-0. Epub 2020 Feb 6. Clin Res Cardiol. 2020. PMID: 32030497 Clinical Trial.
AIMS: To investigate the long-term prognostic value of aspiration thrombectomy in conjunction with primary percutaneous coronary intervention (PCI) compared to conventional PCI in patients with non-ST-elevation myocardial infarction (NSTEMI). ...CONCLUSIONS: In NSTEMI, thr …
AIMS: To investigate the long-term prognostic value of aspiration thrombectomy in conjunction with primary percutaneous coronary inte …
Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.
Kaemmerer AS, Gorenflo M, Huscher D, Pittrow D, Ewert P, Pausch C, Delcroix M, Ghofrani HA, Hoeper MM, Kozlik-Feldmann R, Skride A, Stähler G, Vizza CD, Jureviciene E, Jancauskaite D, Gumbiene L, Ewert R, Dähnert I, Held M, Halank M, Skowasch D, Klose H, Wilkens H, Milger K, Jux C, Koestenberger M, Scelsi L, Brunnemer E, Hofbeck M, Ulrich S, Vonk Noordegraaf A, Lange TJ, Bruch L, Konstantinides S, Claussen M, Löffler-Ragg J, Wirtz H, Apitz C, Neidenbach R, Freilinger S, Nemes A, Opitz C, Grünig E, Rosenkranz S. Kaemmerer AS, et al. Among authors: bruch l. Cardiovasc Diagn Ther. 2021 Dec;11(6):1255-1268. doi: 10.21037/cdt-21-351. Cardiovasc Diagn Ther. 2021. PMID: 35070795 Free PMC article.
Because clinical-trial data on PAH associated with CHD (PAH-CHD) remain limited, registry data on the long-term course are essential. This analysis aimed to update information from the COMPERA-CHD registry on management strategies based on real-world data. ...
Because clinical-trial data on PAH associated with CHD (PAH-CHD) remain limited, registry data on the long-term course are essential. …
Thrombus aspiration in non-ST-elevation myocardial infarction - 12-month clinical outcome of the randomised TATORT-NSTEMI trial.
Meyer-Saraei R, de Waha S, Eitel I, Desch S, Scheller B, Böhm M, Lauer B, Gawaz M, Geisler T, Gunkel O, Bruch L, Klein N, Pfeiffer D, Schuler G, Zeymer U, Thiele H. Meyer-Saraei R, et al. Among authors: bruch l. Eur Heart J Acute Cardiovasc Care. 2017 Feb;6(1):10-17. doi: 10.1177/2048872615617044. Epub 2016 Sep 22. Eur Heart J Acute Cardiovasc Care. 2017. PMID: 26582910 Clinical Trial.
BACKGROUND: In the randomised TATORT-NSTEMI trial routine thrombus aspiration in comparison with standard percutaneous coronary intervention (PCI) did not reduce the primary endpoint of microvascular obstruction assessed by cardiac magnetic resonance imaging in patients with non- …
BACKGROUND: In the randomised TATORT-NSTEMI trial routine thrombus aspiration in comparison with standard percutaneous coronary intervention …
21 results